Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar

(2014) M. A. Karsdal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Evolving therapies for liver fibrosis

(2013) Detlef Schuppan et al.   JOURNAL OF CLINICAL INVESTIGATION

Precise evaluation of liver histology by computerized morphometry shows that steatosis influences liver stiffness measured by transient elastography in chronic hepatitis C

(2013) Jérôme Boursier et al.   JOURNAL OF GASTROENTEROLOGY

Circulating Protein Fragments of Cartilage and Connective Tissue Degradation Are Diagnostic and Prognostic Markers of Rheumatoid Arthritis and Ankylosing Spondylitis

(2013) Anne C. Bay-Jensen et al.   PLoS One

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

(2012) Sudeep Tanwar et al.   HEPATOLOGY

Anti-fibrotic therapy: Lost in translation?

(2012) Detlef Schuppan et al.   JOURNAL OF HEPATOLOGY

Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment

(2012) Marina Berenguer et al.   JOURNAL OF HEPATOLOGY

Protein fingerprints — Relying on and understanding the information of serological protein measurements

(2011) M.A. Karsdal et al.   CLINICAL BIOCHEMISTRY

Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?

(2011) Indra Neil Guha et al.   HEPATOLOGY

A novel assay for extracellular matrix remodeling associated with liver fibrosis: An enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen

(2010) N. Barascuk et al.   CLINICAL BIOCHEMISTRY

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C

(2010) R. J. Fontana et al.   GUT

Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?

(2010) L. Castera et al.   GUT

Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease

(2010) Eric Trépo et al.   JOURNAL OF HEPATOLOGY

Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C

(2010) J. Parkes et al.   JOURNAL OF VIRAL HEPATITIS

Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis

(2010) Sanne S. Veidal et al.   LIVER INTERNATIONAL

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

(2009) John McHutchison et al.   GASTROENTEROLOGY

An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpectII) during albinterferon alfa-2b combination therapy for chronic hepatitis C

(2009) K. Patel et al.   JOURNAL OF VIRAL HEPATITIS

Value of Fibrosis Markers for Staging Liver Fibrosis in Patients With Precirrhotic Alcoholic Liver Disease

(2008) Charles S. Lieber et al.   ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH

Diagnosis and Quantitation of Fibrosis

(2008) Diarmuid S. Manning et al.   GASTROENTEROLOGY

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C

(2008) Robert J. Fontana et al.   HEPATOLOGY

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression

(2008) Hla-Hla Thein et al.   HEPATOLOGY

Exceeding the limits of liver histology markers

(2008) Shruti H. Mehta et al.   JOURNAL OF HEPATOLOGY

Liver biopsy: The best, not the gold standard

(2008) Pierre Bedossa et al.   JOURNAL OF HEPATOLOGY